These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. In vivo susceptibility of Campylobacter pylori. Graham DY; Klein PD; Opekun AR; Smith KE; Polasani RR; Evans DJ; Evans DG; Alpert LC; Michaletz PA; Yoshimura HH Am J Gastroenterol; 1989 Mar; 84(3):233-8. PubMed ID: 2919580 [TBL] [Abstract][Full Text] [Related]
7. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Marshall BJ Rev Infect Dis; 1990; 12 Suppl 1():S87-93. PubMed ID: 2406862 [TBL] [Abstract][Full Text] [Related]
8. [Campylobacter pylori, its detection and association with common pathologic conditions of the gastro-duodenum]. Fixa B; Komárková O; Krejsek J; Bures J; Melichar B; Dvorácek I Vnitr Lek; 1990 Feb; 36(2):170-6. PubMed ID: 2336815 [TBL] [Abstract][Full Text] [Related]
10. Histological aspects of Campylobacter pylori colonisation and infection of gastric and duodenal mucosa. Price AB Scand J Gastroenterol Suppl; 1988; 142():21-4. PubMed ID: 3166530 [TBL] [Abstract][Full Text] [Related]
11. Are antacids cytoprotective? Hollander D; Tarnawski A Gut; 1989 Feb; 30(2):145-7. PubMed ID: 2564832 [No Abstract] [Full Text] [Related]
12. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?]. Menge H Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787 [No Abstract] [Full Text] [Related]
13. [Pharmacological effect and clinical application of protective agents of gastric mucosa]. Si JM; Wang CJ; Wu JG Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2955-7. PubMed ID: 18261319 [No Abstract] [Full Text] [Related]